Foghorn Therapeutics (FHTX) Profit After Tax (2019 - 2026)

Foghorn Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$20.0 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 6.55% year-over-year to -$20.0 million in Q1 2026; TTM through Mar 2026 was -$59.6 million, a 26.32% increase from a year earlier, with the FY2025 full-year figure at -$74.3 million, up 14.22% from the prior year.
• Profit After Tax climbed to -$20.0 million in Q1 2026 per FHTX's latest filing, from -$21.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at $80.9 million in Q4 2022 and bottomed at -$30.5 million in Q1 2023.
• The 5-year median for Profit After Tax is -$20.0 million (2026), against an average of -$8.2 million.
• Across the five-year window, Profit After Tax jumped 377.56% in 2022 and slumped 756.42% in 2023, its largest moves.
• Year by year, Profit After Tax stood at $80.9 million in 2022, then declined by 6.78% to $75.4 million in 2023, then sank by 127.42% to -$20.7 million in 2024, then declined by 4.91% to -$21.7 million in 2025, then climbed by 7.61% to -$20.0 million in 2026.
• Per Business Quant, the three latest FHTX Profit After Tax figures stand at -$20.0 million (Q1 2026), -$21.7 million (Q4 2025), and $68000.0 (Q3 2025).